XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 25, 2022   111,132,993    
Beginning balance at Dec. 25, 2022 $ 541,226 $ 111 $ 1,212,716 $ (671,601)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (33,657)     (33,657)
Exercise of stock options (in shares) 160,964 160,964    
Exercise of stock options $ 767 $ 0 767  
Issuance of common stock related to restricted shares (in shares)   155,558    
Shares repurchased for employee tax withholding (in shares)   6,013    
Shares repurchased for employee tax withholding (44)   (44)  
Stock-based compensation expense 14,265   14,265  
Ending balance (in shares) at Mar. 26, 2023   111,443,502    
Ending balance at Mar. 26, 2023 522,557 $ 111 1,227,704 (705,258)
Beginning balance (in shares) at Dec. 31, 2023   112,639,146    
Beginning balance at Dec. 31, 2023 482,597 $ 113 1,267,469 (784,985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (26,067)     (26,067)
Exercise of stock options (in shares) 257,201 257,201    
Exercise of stock options $ 1,990 $ 0 1,990  
Issuance of common stock related to Spyce milestone achievement (in shares)   208,042    
Issuance of common stock related to Spyce milestone achievement 2,132      
Issuance of common stock related to restricted shares (in shares)   105,371    
Stock-based compensation expense 9,626   9,626  
Ending balance (in shares) at Mar. 31, 2024   113,209,760    
Ending balance at Mar. 31, 2024 $ 470,278 $ 113 $ 1,281,217 $ (811,052)